Highlights

  • Mesoblast (ASX:MSB) reported US$115 million of net Ryoncil revenue for FY2026, with fourth-quarter sales of US$36 million, landing inside its US$110-120 million guidance range.
  • Ryoncil (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy in the United States, cleared for pediatric steroid-refractory acute graft-versus-host disease.
  • The company says 49 US transplant centres had been onboarded against a target of 64 that cover about 94% of relevant transplant activity.
  • Cash stood at roughly US$122 million at 31 March 2026, and management says operations are increasingly funded by product revenue rather than dilutive raisings.
  • Late-stage pipeline programs in end-stage heart failure with LVADs and chronic low back pain are the next value drivers investors will watch.

Mesoblast (ASX:MSB) has spent the better part of two decades as one of the Australian market's most heavily watched, and most frequently doubted, regenerative-medicine stories. For years it was a company defined by promise rather than product: a deep portfolio of cell therapies, a long list of trials, and a share price that lurched with every regulatory update. That characterisation no longer fits. Following US Food and Drug Administration approval of its lead therapy Ryoncil, Mesoblast has crossed the line separating a perpetual development-stage biotech from a genuine commercial enterprise.

The scale of that shift is now visible in the numbers. For the financial year ended 30 June 2026, Mesoblast reported US$115 million in net Ryoncil revenue, including US$36 million in the June quarter alone. After two decades of cash burn, the company is finally selling an approved product at a meaningful and growing rate. The question investors are now asking is no longer whether Mesoblast can get a therapy approved, but whether cell therapy can be commercialised profitably at scale and extended into far larger indications.

What Has Happened

Ryoncil (remestemcel-L) is an allogeneic mesenchymal stromal cell therapy, and it holds a notable distinction: it is the first FDA-approved therapy of its kind in the United States. It is indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged two months and older, a severe and often life-threatening complication that can follow a bone-marrow or stem-cell transplant. For this vulnerable group, treatment options have historically been limited, so the approval addressed a clear unmet need.

Since launch, Mesoblast has focused on embedding Ryoncil within the specialist centres that perform paediatric transplants. The company reported that 49 US transplant centres had been onboarded against a target of 64, a group it says accounts for roughly 94% of the relevant transplant activity in the country, and pointed to encouraging real-world uptake, with around 84% of patients able to complete the initial 28-day treatment regimen. The commercial ramp has been steady rather than explosive: quarterly net revenue rose from US$30.3 million in the March quarter to US$36 million in the June quarter, and the full-year total of US$115 million landed inside the company's guidance range of US$110–120 million.

Why It Matters

For Mesoblast, the significance of a commercial launch goes well beyond a single product line. A business that once relied almost exclusively on equity markets to fund its research is now generating substantial cash from sales, and it says operations are increasingly funded by revenue growth rather than dilutive raisings — a structural change in how the company can finance its ambitions.

It also validates a manufacturing and regulatory model that many observers doubted would ever clear the FDA bar, given how difficult cell therapies are to standardise, manufacture consistently and prove in trials. By securing approval and then showing the product can be sold, reimbursed and delivered across dozens of hospitals, Mesoblast has provided a proof point for the broader field. And because the same cell platform underpins its pipeline, success with Ryoncil is a read-through on what comes next.

Ryoncil, Revascor and the Mesoblast Pipeline

While Ryoncil is the revenue engine, Mesoblast's longer-term case rests on applying its cell platform to conditions far more common than GVHD.

Heart Failure

The heart-failure program, based on the cell product rexlemestrocel-L (historically referred to as Revascor), is arguably the most closely watched pipeline asset. Mesoblast has been engaging with the FDA on a pathway for end-stage heart-failure patients supported by left ventricular assist devices (LVADs), and has indicated it is moving from a filing aimed at accelerated approval toward a filing for full FDA approval, adding that on that basis a separate confirmatory study would not be required. Heart failure is a vastly larger market than SR-aGVHD, so even a narrow indication in LVAD patients could be a strategically important beachhead.

Chronic Low Back Pain

The second major late-stage asset targets chronic low back pain associated with degenerative disc disease, again using rexlemestrocel-L. Mesoblast said it completed the 300-patient enrolment target for its second pivotal Phase 3 trial around March/April 2026. Chronic low back pain is an enormous, poorly served market, and a positive read-out would open a commercial opportunity of a different magnitude — though the trial has yet to report definitive results.

Broadening the Ryoncil Franchise

Mesoblast is also working to widen the Ryoncil label itself. The FDA cleared a label-extension trial in adult SR-aGVHD, which would substantially enlarge the addressable population beyond children, and Mesoblast has secured an IND clearance for a registrational trial in Duchenne muscular dystrophy. Earlier-stage work in biologic-resistant inflammatory bowel disease and, via a licensed chimeric antigen receptor (CAR) platform, in conditions such as ulcerative colitis and lupus nephritis remains speculative and years from market, but illustrates the breadth of the strategy.

Key Financial and Operational Details

The financial profile now reflects a business in transition. Alongside the US$115 million of FY2026 revenue, Mesoblast reported meaningful gross profitability on Ryoncil: in the first half, gross profit excluding amortisation was US$44.2 million on gross sales of about US$57.0 million, a gross margin of roughly 78% before direct selling costs. That margin is central to the company's argument that Ryoncil can fund the rest of the pipeline.

Cash discipline has improved markedly. Net operating cash spend fell to about US$4.1 million in the March quarter, a fraction of the burn rates of the pre-revenue years. Cash and equivalents stood at roughly US$122 million at 31 March 2026, and management has described the capital position as strong, supported by a new five-year facility and growing product revenue. The company did still report a net loss of about US$40.2 million for the first half of FY2026, so statutory profitability is not yet in hand.

Potential Catalysts

Several near-term events could move sentiment. The most consequential would be a formal FDA decision or filing milestone on the heart-failure program. Topline data from the completed chronic low back pain Phase 3 trial would be another major catalyst, in either direction. Progress on the adult SR-aGVHD label extension, continued growth in Ryoncil sales and evidence that the business is approaching operating cash-flow breakeven would also be significant markers.

Material Risks and Uncertainties

The risks remain substantial. Ryoncil addresses a relatively small paediatric population, so the current revenue base, while transformational, is modest by big-pharma standards and concentrated in a single product. The larger pipeline programs in heart failure and back pain are not yet approved, and cell-therapy trials have historically delivered inconsistent results, so a negative Phase 3 read-out or an FDA setback would materially affect the investment case.

The company also carries execution risk in scaling manufacturing and commercial infrastructure, competition, and currency exposure. While Mesoblast says operations are increasingly self-funded, further capital may still be required to advance multiple late-stage programs at once, which could dilute existing shareholders and add to the share-price volatility typical around clinical and regulatory events.

What Investors Should Watch Next

For Mesoblast (ASX:MSB), the signposts from here are reasonably clear. Watch the trajectory of Ryoncil revenue as remaining transplant centres come on board; monitor the heart-failure filing and any FDA feedback on the move toward full approval; and look for topline data from the chronic low back pain Phase 3 trial, a potential company-defining event. Investors should also track the cash position for evidence the business is nearing genuine self-sufficiency.

Conclusion

Mesoblast (ASX:MSB) has achieved something that eluded it for most of its corporate life: it now sells an approved therapy at scale, with US$115 million of first-year Ryoncil revenue and healthy gross margins to show for it. That transition from a cash-burning clinical-stage company to a revenue-generating commercial one is the most important development in its history.

Yet the investment case is far from settled. The current revenue base rests on a single product in a narrow indication, and the far larger prizes in heart failure and chronic low back pain remain dependent on regulatory decisions and trial outcomes that are inherently uncertain. Mesoblast has proven it can commercialise cell therapy; whether it can do so profitably across much bigger markets is the question that will define its next chapter.